3M Prevena Therapy for general surgery
Enhanced general surgery outcomes with Prevena Therapy
A peer-reviewed meta-analysis of 22 studies for various abdominal surgical procedures demonstrated 3M™ Prevena™ Therapy helped significantly reduce the risk of various surgical site complications (SSCs) while helping to improve health economic outcomes compared to standard-of-care dressings.¹
Reduction in SSCs,1*
11 studies; p<0.003†
Reduction in surgical site infections (SSIs),1*
20 studies; p<0.001†
Reduction in readmission,1*
7 studies; p=0.014†
*Relative risk reduction.
†Calculation(s) are derived based on the relative patient group incidence rate reporting in this study. Statistically significant (p<0.05).
The effectiveness of Prevena Therapy in reducing the incidence of SSIs and seroma in all surgical procedures and populations has not been demonstrated. See full indications for use and limitations at hcbgregulatory.3M.com.
Proactive risk management (PRM)
Access comprehensive resources to implement PRM into your practice with Prevena Therapy, helping to elevate your standard of patient care with proven postoperative benefits.
Prevena Therapy video resources
Explore more
Abstracts
Discover abstracts from prominent research papers on topics related to Prevena Therapy, offering valuable scientific findings and perspectives.
- Closed incision negative pressure wound therapy is associated with reduced surgical site infection after emergency laparotomy: A propensity matched-cohort analysis
- Closed-incision negative-pressure therapy in high-risk general surgery patients following laparotomy: A retrospective study
- Prophylactic closed‐incision negative‐pressure wound therapy is associated with decreased surgical site infection in high‐risk colorectal surgery laparotomy wounds
- Prophylactic negative-pressure dressings reduce wound complications and burden after emergency laparotomies
- Closed-incision negative pressure therapy decreases wound morbidity in open wall reconstruction with concomitant panniculectomy
- Closed incision negative pressure therapy achieves better outcome than standard wound care: Clinical outcome and cost-effectiveness analysis in open ventral hernia repair with synthetic mesh positioning
- Negative pressure wound therapy for surgical-site infections: A randomized trial
Explore more
Product information
Explore detailed resources including brochures, coding sheets and other informational resources offering comprehensive insights into Prevena Therapy for general surgery.
Abstracts
Discover abstracts from prominent research papers on topics related to Prevena Therapy, offering valuable scientific findings and perspectives.
- Negative pressure wound therapy for surgical-site infections: A randomized trial
- Closed-incision negative-pressure therapy in high-risk general surgery patients following laparotomy: A retrospective study
- Prophylactic closed‐incision negative‐pressure wound therapy is associated with decreased surgical site infection in high‐risk colorectal surgery laparotomy wounds
- Closed incision negative pressure wound therapy is associated with reduced surgical site infection after emergency laparotomy: A propensity matched-cohort analysis
- Prophylactic negative-pressure dressings reduce wound complications and burden after emergency laparotomies
- Closed-incision negative pressure therapy decreases wound morbidity in open wall reconstruction with concomitant panniculectomy
- Closed incision negative pressure therapy achieves better outcome than standard wound care: Clinical outcome and cost-effectiveness analysis in open ventral hernia repair with synthetic mesh positioning
NOTE:
Specific indications, limitations, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. Rx only.
Indication(s) For Use / Intended Use: US FDA Cleared: Only for Use in the United States:
Prevena Dressing used with Prevena Therapy Units: PREVENA™ 125 and PREVENA PLUS™ 125 Therapy Units manage the environment of closed surgical incisions and remove fluid away from the surgical incision via the application of -125mmHg continuous negative pressure. When used with legally marketed compatible PREVENA™ dressings for up to seven days, PREVENA™ 125 and PREVENA PLUS™ 125 Therapy Units are intended to aid in reducing the incidence of seroma; and in patients at high risk for post-operative infections, aid in reducing the incidence of superficial surgical site infection in Class I and Class II wounds.
Limitations:
- The device is not intended to treat surgical site infection or seroma.
- Safety and effectiveness in pediatric population (<22 years old) have not been evaluated.
- Safety and effectiveness in Class III (Contaminated) and Class IV (Dirty/Infected) wounds have not been demonstrated. Furthermore, Class IV surgical wounds are not expected to be closed primarily, and the subject device should only be used on closed surgical incisions.
- The device has not been demonstrated to reduce deep incisional and organ space surgical site infections.
- The device has not been demonstrated to be effective in reducing the incidence of surgical site infection and seroma in all surgical procedures and patient populations; therefore, the device may not be recommended for routine use to reduce the incidence of surgical site infection and seroma.
- Please refer to the ‘Summary of Clinical Information’ section for the specific surgical procedures and patient populations included in the clinical studies. Surgeons should continue to follow the ‘Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection’2 and the ‘American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines’3 for best practices in preventing surgical site infection. US FDA Cleared: Dressings/ Systems (Prevena Dressings used with compatible Solventum NPWT units - ActiVAC, Ulta, and RX4) and applicable OUS countries that leverage US Indication: The PREVENA™, PREVENA PLUS™, PREVENA DUO™, and PREVENA RESTOR™ Incision Management Systems are intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudates via the application of negative pressure wound therapy.
References:
- Mantyh C, Silverman R, Collinsworth A, Bongards C, Griffin L. ePlasty. 2024;24:e33. Closed incision negative pressure therapy versus standard of care over closed abdominal incisions in the reduction of surgical site complications: A systematic review and metaanalysis of comparative studies
- Berríos-Torres, S. I., Umscheid, C. A., Bratzler, D. W., Leas, B., Stone, E. C., Kelz, R. R., Reinke, C. E., Morgan, S., Solomkin, J. S., Mazuski, J. E., Dellinger, E. P., Itani, K. M., Berbari, E. F., Segreti, J., Parvizi, J., Blanchard, J., Allen, G., Kluytmans, J. A., Donlan, R., & Schecter, W. P. (2017). Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017. JAMA Surgery, 152(8), 784. https://doi.org/10.1001/jamasurg.2017.0904
- Ban, K. A., Minei, J. P., Laronga, C., Harbrecht, B. G., Jensen, E. H., Fry, D. E., Itani, K. M. F., Dellinger, P. E., Ko, C. Y., & Duane, T. M. (2017). American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 update. Journal of the American College of Surgeons, 224(1), 59–74. https://doi.org/10.1016/j.jamcollsurg.2016.10.029